Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerstin N Vokinger

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Cell|April 14, 2023
Determinants of cancer drug pricing and how to overcome the cancer premiumKerstin N Vokinger
JAMA Health Forum|December 28, 2023
Do Managed Entry Agreements Contribute to Lower Pharmaceutical Spending?Kerstin N Vokinger
The Lancet. Oncology|August 9, 2025
The importance of high-quality evidence supporting cancer drug approvalsKerstin N Vokinger
Nature Machine Intelligence|October 4, 2021
Regulating AI in medicine in the United States and EuropeKerstin N Vokinger, Urs Gasser
JAMA Health Forum|December 22, 2022
Negotiating Drug Prices in the US-Lessons From EuropeKerstin N Vokinger, Huseyin Naci
Nature Medicine|May 10, 2022
Adverse effects of acquisitions in the pharmaceutical industryMelissa Newham, Kerstin N Vokinger
Nature Reviews. Clinical Oncology|September 24, 2021
Value-based pricing of drugs with multiple indications or in combinations - lessons from EuropeKerstin N Vokinger, Aaron S Kesselheim
The Lancet Regional Health. Europe|April 26, 2021
Patients' access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in EuropeDavid L Carl, Kerstin N Vokinger
The Lancet. Oncology|February 3, 2022
New EU regulation on health technology assessment of cancer medicinesThomas J Hwang, Kerstin N Vokinger
Health Policy (Amsterdam, Netherlands)|December 29, 2019
Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018Kerstin N Vokinger, Urs Jakob Muehlematter
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Cell|April 14, 2023
Determinants of cancer drug pricing and how to overcome the cancer premiumKerstin N Vokinger
JAMA Health Forum|December 28, 2023
Do Managed Entry Agreements Contribute to Lower Pharmaceutical Spending?Kerstin N Vokinger
The Lancet. Oncology|August 9, 2025
The importance of high-quality evidence supporting cancer drug approvalsKerstin N Vokinger
Nature Machine Intelligence|October 4, 2021
Regulating AI in medicine in the United States and EuropeKerstin N Vokinger, Urs Gasser
JAMA Health Forum|December 22, 2022
Negotiating Drug Prices in the US-Lessons From EuropeKerstin N Vokinger, Huseyin Naci
Nature Medicine|May 10, 2022
Adverse effects of acquisitions in the pharmaceutical industryMelissa Newham, Kerstin N Vokinger
Nature Reviews. Clinical Oncology|September 24, 2021
Value-based pricing of drugs with multiple indications or in combinations - lessons from EuropeKerstin N Vokinger, Aaron S Kesselheim
The Lancet Regional Health. Europe|April 26, 2021
Patients' access to drugs with rebates in Switzerland - Empirical analysis and policy implications for drug pricing in EuropeDavid L Carl, Kerstin N Vokinger
The Lancet. Oncology|February 3, 2022
New EU regulation on health technology assessment of cancer medicinesThomas J Hwang, Kerstin N Vokinger
Health Policy (Amsterdam, Netherlands)|December 29, 2019
Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018Kerstin N Vokinger, Urs Jakob Muehlematter
Pageof 6